7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heptadecafluorotetradecane-1-thiol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醇
• 英文名称: 7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heptadecafluorotetradecane-1-thiol
• 英文别名: 7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptadecafluorotetradecane-1-thiol
• 化学式: C₁₄H₁₃F₁₇S
• 分子量: 536.29
• InChiKey: TZWNXHDTCWZYPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  18

文献信息

• Antigen delivery vectors and constructs
  申请人：ALTIMMUNE UK LIMITED

  公开号：EP2374477B1

  公开（公告）日：2016-09-07
• [EN] VACCINES AGAINST HEPATITIS B VIRUS<br/>[FR] PRODUIT THÉRAPEUTIQUE CONTRE VHB
  申请人：IMMUNE TARGETING SYSTEMS ITS LTD

  公开号：WO2014102540A1

  公开（公告）日：2014-07-03

  A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
• [EN] ONCOLOGY VACCINE<br/>[FR] VACCIN ONCOLOGIQUE
  申请人：IMMUNE TARGETING SYSTEMS ITS LTD

  公开号：WO2015033140A1

  公开（公告）日：2015-03-12

  A pharmaceutical composition comprising at least two peptides of from 20 to 60 amino acids in length, selected from peptides comprising a sequence of at least 20 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 40 and 48 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: 1 to 40 and 48, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope.